Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: GILD

Gilead Sciences, Inc.

Healthcare | Drug Manufacturers - General
$131.27 +1.91 (+1.47%) as of 2026-07-14 13:09 UTC
Volume7.65M
EPS (TTM)$6.78

Gilead Sciences, Inc. (NASDAQ: GILD) is a drug manufacturers - general company trading at $131.27 (+1.5% today) — 19.4× trailing earnings, yielding 2.43%. Figures from SEC EDGAR and market feeds; updated 2026-07-14 13:09 UTC.

52-Week Range
Low $93.37High $157.29

What Gilead Sciences, Inc. does

Gilead Sciences is a biopharmaceutical company that discovers, develops, and delivers medicines to treat diseases including HIV, viral hepatitis, COVID-19, and cancer. The company operates in more than 35 countries with headquarters in Foster City, California. In 2025, Gilead's commercial portfolio included more than 25 therapies across therapeutic areas such as virology and oncology, with products like Biktarvy and Descovy for HIV treatment, Epclusa for hepatitis C, and Tecartus and Yescarta for certain cancers.

Summarized from Gilead Sciences, Inc.’s SEC filings · Read the filing ↗

Key facts
Quote
Price$131.27
Change (1D)+1.91 (+1.47%)
Volume7.65M shares
52-week range$93.37 – $157.29
Valuation
P/E (TTM)19.36×
EPS (TTM)$6.78
Dividend yield2.43%
Return on equity37.62%
Debt/equity1.10
Returns
52-week return+40.6%
Revenue, margins & earnings
FY2021 Net income: $6.22BFY2021 Taxes & interest: $3.69BFY2021 Operating costs: $17.4B$27.3BFY2021FY2022 Net income: $4.59BFY2022 Taxes & interest: $2.74BFY2022 Operating costs: $20.0B$27.3BFY2022FY2023 Net income: $5.67BFY2023 Taxes & interest: $1.94BFY2023 Operating costs: $19.5B$27.1BFY2023FY2024 Net income: $480MFY2024 Taxes & interest: $1.18BFY2024 Operating costs: $27.1B$28.8BFY2024FY2025 Net income: $8.51BFY2025 Taxes & interest: $1.51BFY2025 Operating costs: $19.4B$29.4BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
Annual revenue; bands show net, operating margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-02
  • 2026-07-02O'Day Daniel PatrickChairman & CEOSELL-11,900$1.50M
  • 2026-07-02O'Day Daniel PatrickChairman & CEOSELL-3,100$393.9K
  • 2026-06-16Mercier JohannaChief Comm & Corp Aff OfficerSELL-1,070$132.7K
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • BlackRock, Inc.117,460,002$16.37B-4.7%
  • VANGUARD GROUP INC121,094,977$14.86B+1.8%
  • VANGUARD CAPITAL MANAGEMENT LLC80,654,776$11.24BNEW
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does Gilead Sciences, Inc. do?

Gilead Sciences is a biopharmaceutical company that discovers, develops, and delivers medicines to treat diseases including HIV, viral hepatitis, COVID-19, and cancer.

What is GILD's valuation?

GILD trades at $131.27, 19.36× trailing earnings, as of 2026-07-14. It carries a 2.43% dividend yield.

When did GILD last file with the SEC?

Gilead Sciences, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-05-07. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-14 13:09 UTC. This page is also available as JSON at /api/data?ticker=GILD and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for GILD and 3,500+ tickers.

Create a free account — keep GILD
For your agent
GET /api/data?ticker=GILD

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt